<!--? Tables Docs ?-->
<!-- https://www.yourhtmlsource.com/tables/nestingtables.html -->
<!-- https://www.yourhtmlsource.com/tables/basictables.html -->
<!-- https://www.yourhtmlsource.com/tables/advancedtables.html -->


<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PTM Code Test</title>
</head>

<body style="margin: 0 10% 0 10%; border: solid #000 1px;">



    <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr>
            <!-- Table Wrapper -->
            <td align="center">
                <img style="width: 100%;" src="img/header.png" alt="Header Image">
            </td>
        </tr>
        <tr>
            <td style="padding: 0 30px 20px 30px;">
                <h4>Apobiologix® supports your patients</h4>
                <p>Your Grastofil® patients are also supported through the ANSWERS patient support program, which:
                    <br>
                    • Offers comprehensive reimbursement assistance.
                    <br>
                    • Helps maximizes access and minimizes time to treatment.</p>
                <p>Enrol your patients in the ANSWERS patient support program today! Visit apoanswers.ca.</p>
            </td>
        </tr>
    </table>


    <table width=100%>
        <tr>
            <td width=55% style="border-top: solid #fca503 3px; border-bottom: solid #fca503 3px;">
                <table width=100%>
                    <tr>
                        <td><img style="float: left;" src="img/qmark.png"
                                alt="Question Mark Image">
                            <h4 style="margin: 10px 0;"><b>Questions?</b></h4>
                            <p style="margin: 0;">Contact your Apobiologix Biosimilar Consultant:</p>
                        </td>

                    </tr>
                    <tr>
                        <td>
                           <form style="padding-left: 80px;">
                               <label for="name">Name: </label>
                               <br>
                               <input type="text"> 
                               <br>
                               <label for="email">Email: </label>
                               <br>
                               <input type="email">
                               <br>
                               <label for="number">Phone Number: </label>
                               <br>
                               <input type="tel">
                               <br><br>
                               <input type="submit" value="Submit">
                           </form> 

                        </td>
                    </tr>
                </table>

            </td>
            <td width=4%></td>
            <td width=35% style="background-color: lightgreen;"">
                <table style="margin:0 ; padding:30% 0; border: #fff solid 4px;" >
                <tr>
                    <td>
                <p style= "padding: 0; margin: 0;"> 
                    Grastofil ® is developed and
                    marketed by Apobiologix ® ,
                    a Canadian pharmaceutical
                    company dedicated
                    to biosimilars.
                </p>
            </td>
            </tr>
        </table>
            </td>
        </tr>
    </table>

    <table width=100%>
        <tr>
            <h4 style="text-decoration: underline; font-weight: bold;">Indications and clinical use:</h4>
            <p>Grastofil ® (filgrastim) is indicated for the following:</p>

            <p><b>Cancer Patients Receiving Myelosuppressive Chemotherapy</b><br>
                Grastofil ® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia,
                in patients with
                non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.</p>
            <p>Grastofil ® is indicated in adult and pediatric patients with cancer receiving myelosuppressive
                chemotherapy.</p>
            <p>A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy and twice per
                week during
                Grastofil ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical
                studies, filgrastim therapy
                was discontinued when the ANC was > 10 × 10 9 /L after expected chemotherapy-induced nadir.</p>
            <p>Please consult the complete Product Monograph at
                <a
                    href="https://health-products.canada.ca/dpd-bdpp/index-eng.jsp">https://health-products.canada.ca/dpd-bdpp/index-eng.jsp</a>
                for complete
                indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing and
                conditions of clinical use.
                The Product Monograph is also available by calling DISpedia, Apotex’s Drug Information Service, at:
                1-800-667-4708.</p>
            <p>© 2017, Apotex Technologies Inc.</p>
            <p>Apobiologix ® and Grastofil ® are trademarks of Apotex Technologies Inc.</p>
            <p>Neupogen is a trademark of Amgen Inc.</p>
        </tr>
    </table>

    <table width=100%>
        <tr align="center">
            <td><img style="width: 100%;" src="img/footer1.png" alt="First footer image"></td>
            <td><img style="width: 100%;" src="img/footer2.png" alt="Second footer image"></td>
            <td><img style="width: 100%;" src="img/footer3.png" alt="Third footer image"></td>
        </tr>
    </table>
</body>

</html>